EMA: We're firmly convinced of the benefits of the Astrazeneca vaccine
The EMA is investigating reports of blood clots following the Astrazeneca vaccine, but does not change its recommendation.
BY RITZAU, TRANSLATED BY NIELSINE NIELSEN
The European Medicines Agency (EMA) remains "highly convinced" that the benefits of the Astrazeneca vaccine outweigh its risks, according to EMA Executive Director Emer Cooke at a Tuesday press conference.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA starts rolling review for Eli Lilly's Covid-19 treatment
For subscribers
Denmark suspends Astrazeneca vaccinations
For subscribers
